04:32 PM EST, 03/06/2025 (MT Newswires) -- Profound Medical ( PROF ) edged down in after-hours Nasdaq after the company on THursday said its fourth-quarter narrowed as revenue more than doubled.

The medical-device company said it US$4.9 million, or US$0.20 per share, in the period, compared with a loss of US$8.9 million, or US$0.42, in the prior-year period.

Revenue surged 108% to US$4.2 million, with US$2.7 million from recurring, non-capital revenue. The company said it continued to see a variety of prostate disease patients being treated by its TULSA-PRO procedure.

The Level 1 CAPTAIN trial has completed patient enrollment and Profound expects to release available data from the trial at the American Urological Association's annual meeting in April.

"2024 marked the final year in which we were operating in a primarily patient-pay environment for TULSA," said Arun Menawat, Profound's chief executive. "Moving forward, with the TULSA procedure now being uniquely reimbursed both at Urology APC Level 7 and at an unrivalled number of treatment settings, and with initial data readouts from our CAPTAIN clinical trial coming this year ... we believe that we are entering into a stage of anticipated escalating growth."

Profound Medical ( PROF ) was last seen down US$0.02 to US$7.27 after hours. They closed up $0.04 to $10.34 on the Toronto Stock Exchange.